#iganephropathy — Public Fediverse posts

Budesonide for IgA-Nephropathy, Phase 3

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01554-4/fulltext?rss=yes

Does the company have the guts to do a head-to-head-trial against regular budesonide?

#nephrology #IgANephropathy

This is the methods section of interest - RASi ‘optimized’ ie the maximum tolerated dose had to be at least 50% of max (😏) and BP < 150/100

Note biopsy timing doesn’t matter

Note exclusion for heart failure (Endothelin antagonist specific issue!)

This is the interim result for FDA approval (obtained) of 36 week follow up, final follow up is 114 weeks, plus an observational period

#Sparsentan #IgANephropathy

2/

Headline result from the #Sparsentan PROTECT trial in #IgANephropathy in #Lancet https://authors.elsevier.com/c/1grIl_3CjG8WAP

1/🧵

Full text link via @Rheault_m

Big proteinuria reduction:

This is the methods section of interest - RASi ‘optimized’ ie the maximum tolerated dose had to be at least 50% of max (😏) and BP < 150/100

Note biopsy timing doesn’t matter

Note exclusion for heart failure (Endothelin antagonist specific issue!)

This is the interim result for FDA approval (obtained) of 36 week follow up, final follow up is 114 weeks, plus an observational period

#Sparsentan #IgANephropathy

2/

Headline result from the #Sparsentan PROTECT trial in #IgANephropathy in #Lancet https://authors.elsevier.com/c/1grIl_3CjG8WAP

1/🧵

Full text link via @Rheault_m

Big proteinuria reduction:

The rationale and design of the APPLAUSE IgAN trial of #iptacopan - a complement inhibitor - in #IgANephropathy - funded by its maker Novartis

Well timed for #NephMadness #IgANephropathy region! With a great #VisualAbstract from @edgarvlermamd

https://www.sciencedirect.com/science/article/pii/S2468024923000505

The rationale and design of the APPLAUSE IgAN trial of #iptacopan - a complement inhibitor - in #IgANephropathy - funded by its maker Novartis

Well timed for #NephMadness #IgANephropathy region! With a great #VisualAbstract from @edgarvlermamd

https://www.sciencedirect.com/science/article/pii/S2468024923000505

Tonight and tomorrow on #NephJC we discuss the NEFIGARD trial of #Nefecon (a targeted release #budesonide) in #IgANephropathy - supposedly with no systemic steroid exposure - but read the summary and decide for yourself http://www.nephjc.com/news/nefigard-trial

#nephrology #glomerulonephritis

#VisualAbstract from @Priti899

For a snapshot of all the trials so far, see this table made by Divya Bajpai

#iGANephropathy #NephJC